Literature DB >> 1722079

Selective anabolism of 6-methoxypurine arabinoside in varicella-zoster virus-infected cells.

K K Biron1, P de Miranda, T C Burnette, T A Krenitsky.   

Abstract

6-Methoxypurine arabinoside (ara-M) is a highly selective inhibitor of varicella-zoster virus (VZV). It belongs to a class of purine arabinosides whose anti-VZV activity in vitro correlates with substrate utilization by the VZV-encoded thymidine kinase (TK) (D. R. Averett, G. W. Koszalka, J. A. Fyfe, G. B. Roberts, D. J. M. Purifoy, and T. A. Krenitsky, Antimicrob Agents Chemother. 35:851-857, 1991). In this study, the mechanism of action of ara-M was explored. VZV-infected human fibroblasts selectively accumulated ara-M and its phosphorylated metabolites, whereas in uninfected fibroblasts or in those infected with a TK-deficient strain of VZV, there was virtually no cellular uptake of ara-M. The major intracellular metabolite of ara-M in VZV-infected cells was identified as the triphosphate of adenine arabinoside (ara-ATP). Appreciable levels of ara-ADP, ara-AMP, and ara-MMP were also detected. However, di- or triphosphorylated forms of ara-M were not detected. Moreover, in VZV-infected cells, the concentrations of ara-ATP which accumulated in the presence of ara-M were up to eightfold higher than those generated with ara-A itself. In contrast, in uninfected cells, the levels of ara-ATP which accumulated in the presence of ara-M were barely detectable. Clearly, Ara-M activation was dependent on the activity of the virus-encoded TK, while ara-A anabolism resulted primarily from the activity of host cell enzymes. Therefore, ara-M selectively generates the DNA polymerase inhibitor ara-ATP in the VZV-infected cell.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722079      PMCID: PMC245336          DOI: 10.1128/AAC.35.10.2116

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus.

Authors:  D R Averett; G W Koszalka; J A Fyfe; G B Roberts; D J Purifoy; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Anabolic pathway of 6-methoxypurine arabinoside in cells infected with varicella-zoster virus.

Authors:  P de Miranda; T C Burnette; K K Biron; R L Miller; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

3.  Herpes zoster encephalitis: successful therapy with vidarabine.

Authors:  S J Wees; T Madhavan
Journal:  Henry Ford Hosp Med J       Date:  1980

4.  Growth inhibition by acycloguanosine of herpesviruses isolated from human infections.

Authors:  C S Crumpacker; L E Schnipper; J A Zaia; M J Levin
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

5.  Antiviral activity of arabinosyladenine and arabinosylhypoxanthine in herpes simplex virus-infected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in synchronized suspension cultures.

Authors:  C Shipman; S H Smith; R H Carlson; J C Drach
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

6.  Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients.

Authors:  R J Whitley; S J Soong; R Dolin; R Betts; C Linnemann; C A Alford
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

7.  Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study.

Authors:  R J Whitley; S J Soong; R Dolin; G J Galasso; L T Ch'ien; C A Alford
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

8.  Antiviral activity of arabinosyladenine and arabinosylhypoxanthine in herpes simplex virus-infected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in the presence of an adenosine deaminase inhibitor.

Authors:  P M Schwartz; C Shipman; J C Drach
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

9.  Metabolic disposition and pharmacokinetics of the antiviral agent 6-methoxypurine arabinoside in rats and monkeys.

Authors:  T C Burnette; G W Koszalka; T A Krenitsky; P De Miranda
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  CONVERSION OF MONO- AND OLIGODEOXYRIBONUCLEOTIDES TO 5-TRIPHOSPHATES.

Authors:  D E HOARD; D G OTT
Journal:  J Am Chem Soc       Date:  1965-04-20       Impact factor: 15.419

View more
  2 in total

1.  Anabolic pathway of 6-methoxypurine arabinoside in cells infected with varicella-zoster virus.

Authors:  P de Miranda; T C Burnette; K K Biron; R L Miller; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

2.  Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.

Authors:  Janarthanan Narayanasamy; Manik R Pullagurla; Ashoke Sharon; Jianing Wang; Raymond F Schinazi; Chung K Chu
Journal:  Antiviral Res       Date:  2007-03-30       Impact factor: 5.970

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.